Table 4 Drugs that alter cellular redox balance in MDS cells
From: Role of reactive oxygen species in myelodysplastic syndromes
Compound | Results | Ref. |
|---|---|---|
AZA | ↑ ROS; ↑ GSSG/GSH; ↑ lipid peroxidation; ↓ GSH | Montes et al. [214] |
DAC | ↑ ROS; ↓ MMP | Wang et al. [222] |
DAC combined with ATO | ↑ ROS; ↑ ER stress | Huang et al. [227] |
ATO combined with triptolide | ↑ ROS; ↑ Bax; ↑ caspase-3; ↓ BCL-2 | Hua et al. [290] |
DAC combined with ATRA | ↑ ROS; ↑ RARα-Nrf2 complex; ↓ Nrf2 | Wang et al. [228] |
T-dCyd combined with venetoclax | ↑ ROS; ↓ Nrf2; ↓ HO-1; ↓ BCL-2 | Hu et al. [291] |
Withaferin A | ↑ ROS; activation of JNK/AP-1 signaling | Oben et al. [292] |
Luteolin | ↑ ROS; ↑ Bax/BCL‑2; ↑ activity of caspase-3, -8, -9 | Dong et al. [293] |
Ascorbic acid | ↑ ROS; cell cycle arrest | Niu et al. [294] |
Fucoidan | ↑ ROS; ↑ caspase-3, -8, -9 | Wei et al. [295] |
DFX | ↓ ROS; ↓ DNA oxidative damage | Jiméne et al. [239] |